This page contains recent news articles, when available, and an overview of but does not offer medical advice. You should contact your physician with regard to any health issues or concerns. Background information on Fabry sufferers, others with rare conditions mark international ...  -  Feb 29, 2008 ChronicleHerald.ca,Members of the Fabry Disease Society of Nova Scotia are pleased the province has proclaimed the awareness day. Only about 250 Canadians have the rare VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of ...  -  Feb 29, 2008 FOXBusinessFabry Disease (also known as Anderson-Fabry Disease) is a lysosomal storage disease with an estimated birth incidence of 1 in 117000. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical ...  -  Mar 13, 2008 PharmaLive.com (press release),Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for BUYINS.NET: TLB, NGD, CTIC, FOLD, OPXA, PALM Have Been On BUYINS ...  -  Mar 14, 2008 Trading Markets (press release),The company's products include Amigal, which has completed Phase II clinical trial for the treatment of Fabry disease; Plicera, a Phase II clinical trial Food for Thought  -  Mar 4, 2008 Morris Daily Herald,...“You need to start eating healthy,â€? the doctor said minutes before I was to undergo my most recent IV treatment for Fabry disease. Alberta teen pleads for $500000 drug therapy  -  Feb 29, 2008 CBC Ottawa,Koning himself suffers from Fabry disease, a disorder that interferes with the body's ability to break down fatty substances. "It's to make our politicians SWLA's Children's Miracle Network Champions  -  Mar 18, 2008 KPLC-TV,Nathan and Bradley Rowell were diagnosed three years ago with a rare genetic disorder - in fact, they are the only known twins to have Fabry's disease. Enzyme replacement improves cardiomyopathy in Anderson-Fabry disease  -  Feb 18, 2008 Medicexchange,Enzyme replacement with agalsidase alfa results in regression of hypertrophic cardiomyopathy in patients with Anderson-Fabry disease, an X-linked Samaritan to Launch REPLAGAL® for Fabry Disease in Greece and Cyprus  -  Feb 5, 2008 Free press releases (press release),REPLAGAL(r) is a long-term enzyme replacement therapy used to treat patients with a confirmed diagnosis of Fabry Disease. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 ...  -  Jan 29, 2008 CNNMoney.comIn December 2007, Amicus announced positive results from its Phase 2 clinical trials of Amigal(TM) for Fabry disease. 26 patients completed the study, Genzyme Corp swings into the black for fourth quarter  -  Feb 14, 2008 Pharma Times (subscription),Revenues rose 21% to $1.04 billion, driven by sales of Gaucher disease treatment Cerezyme (imiglucerase), up 15% to $301 million and Fabry disease drug Drug maker Shire promises 680 jobs  -  Feb 13, 2008 Boston Globe,Shire's Human Genetic Therapies unit, which develops drugs to address rare medical disorders such as Fabry disease, is based in Cambridge, Amicus Therapeutics to Present at the BIO CEO & Investor ...  -  Feb 7, 2008 CNNMoney.comAmicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the Genzyme Meets Views, Sees Strong Revenue  -  Feb 13, 2008 TheStreet.comFabry disease treatment Fabrazyme and Pompe disease treatment Myozyme generated sales of $114 million and $62 million, respectively. Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year  -  Feb 14, 2008 Lifescience-online,The European Commission has granted full marketing authorization for Fabrazyme, making the product the only Fabry disease treatment to earn this designation Biotech Company Specializes In Treatments For Rare Disorders  -  Jan 23, 2008 CNNMoney.comThe drug helps treat Fabry's disease, estimated to affect 5000 to 7000 people worldwide. The firm's emerging segments, including its renal franchise, Genzyme Turns To Profit In Q4 On Strong Drug Sales; Guides Q1 ...  -  Feb 13, 2008 RTT News,Sales of the company's Fabry disease treatment Fabrazyme increased 18% to $114 million from $97 million in the same quarter last year. For Fiscal year 2007, British drugmaker Shire to expand in Massachusetts, add 680 jobs  -  Feb 14, 2008 PR-Inside.com (Pressemitteilung),...in developing treatments for genetic and rare disease. The unit's key products are Elaprase, to treat Hunter syndrome, and Replagal, for Fabry disease. Little Daisy's life was saved thanks to a  -  Jan 24, 2008 Checkbiotech.org (press release),Fabry disease - a disorder which affects blood vessels including in the brain, kidneys and heart. The centre anticipates five to 10 new cases each year. Cayuga Fund Up 6% in Volatile Year  -  Jan 24, 2008 Black Enterprise,A compound developed to treat the Fabry disease received mixed results in clinical trials last month, sending the stock spiraling downward and dealing a Amicus sees positive Phase II data for Fabry disease candidate  -  Dec 19, 2007 ReutersO: Quote, Profile, Research) said it had positive results from Phase II clinical trials of Amigal for Fabry disease. Based on the results, Amicus said it Fabry's drug outlook sinks Amicus shares  -  Dec 20, 2007 BusinessWeekLate Wednesday, Amicus said drug candidate Amigal met safety and tolerability goals in a midstage study for Fabry's disease, a rare hereditary disorder that Amicus Therapeutics Announces Positive Results From Phase 2 ...  -  Dec 19, 2007 CNNMoney.comThe four open-label, multi-national Phase 2 trials of Amigal enrolled 18 men and 9 women with Fabry disease between the ages of 17 and 65. Amicus Therapeutics Reports Positive Phase 2 Data Of Amigal For ...  -  Dec 19, 2007 Trading Markets (press release),Also, the data demonstrated that Amigal has a meaningful effect on a range of genetic mutations in Fabry disease and thus has the potential to treat a Biotech Notebook: Genitope, Amicus, Introgen  -  Dec 21, 2007 TheStreet.comAmicus Therapeutics (FOLD - Cramer's Take - Stockpickr) presented some phase II data on its Fabry disease drug Amigal on Wednesday. Amicus Experimental Drug Meets Goals  -  Dec 19, 2007 Houston Chronicle,Fabry disease is caused by genetic mutations in the GLA gene, which result in deficient activity of an enzyme called a-GAL. Deficient a-GAL can ultimately FOLD: Plunges to 52-Week Low Despite Positive Ph II Data for ...  -  Dec 20, 2007 Therapeutics Daily (subscription) (press release),Fabry disease is caused by the lack of or faulty enzyme needed to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids. Amicus reports positive results for Amigal  -  Dec 21, 2007 Trading Markets (press release),PowerRating -- Amicus Therapeutics has presented positive results from its recently completed Phase II clinical trials of Amigal for Fabry disease. Genzyme "outperform"  -  Dec 20, 2007 newratings.com,...the analysts mention that the Phase II data for Amicus’ Amigal drug, which competes with Genzyme’s Fabrazyme for the treatment of Fabry's disease, $40.5m in incentives pledged to keep drug firm's plans on track  -  Dec 21, 2007 Boston Globe,Shire makes several drugs, including Elaprase for Hunter syndrome and Replagal for Fabry disease. As part of the expansion project, the company would move Amicus Therapeutics to Host R&D Day  -  27 Nov 2007 CNNMoney.comThe presentation will include a summary of the results of the Phase 2 clinical trials performed for Amigal(TM) (migalastat hydrochloride) for Fabry disease amicus therapeutics and shire plc enter into $440 million ex-us ...  -  Nov 8, 2007 CNNMoney.com...trials for the treatment of fabry disease, plicera(tm) (isofagomine tartrate) currently in phase 2 clinical trials for the treatment of gaucher disease, shire expands its human genetic therapies pipeline through in ...  -  Nov 8, 2007 CNNMoney.com...which includes replagal(tm) for fabry disease, elaprase(tm) for hunter syndrome and ga-gcb in phase 3 development for gaucher disease. in addition, amicus, shire team on rare gene r&d  -  Nov 8, 2007 TheStreet.com...(shire also owns replagal to treat the genetic disorder fabry disease.) the diseases belong to a class of lysosomal storage disorders, which are caused by a shire signs rare disease drug licensing deal with amicus  -  Nov 9, 2007 Checkbiotech.org (press release),...three investigational compounds that treat rare genetic disorders. shire has licensed the ex-us rights to amicus’ amigal (migalastat) for fabry disease, shire pads genetic disease therapeutic pipeline through $440m ...  -  Nov 8, 2007 Genetic Engineering News (press release),...million upfront for three compounds in markets outside of the united states: phase ii amigalâ„¢ for fabry disease, phase ii pliceraâ„¢ for gaucher disease, lsd deal brings amicus $50m now, $390m later  -  Nov 8, 2007 BioWorld Online,...shire gets ex-us development and commercialization rights to the phase ii fabry disease drug amigal (migalastat hydrochloride), the phase ii gaucher thursday's health winners & losers  -  Nov 8, 2007 TheStreet.com...goucher's disease and fabry disease. shares rose 67 cents, or 4.2%, to $16.75. elsewhere, earnings ruled (and sometimes ruined) the day. king pharma (kg shire partners with amicus on development  -  Nov 8, 2007 Conde Nast Portfolio,...mass., said the compounds will be used to develop therapies for lysosomal storage disorders, including fabry disease, gaucher disease and pompe disease. update 1-amicus therapeutics signs licensing deal with shire  -  Nov 9, 2007 Reuters...a company that developed a drug called replagal to treat the genetic disorder fabry disease. shire also sells elaprase, a drug for hunter syndrome. shire licenses drugs for rare diseases mass high tech: the journal ...  -  Nov 8, 2007 Bizjournals.com,...in markets outside of the united states. new jersye's amicus licensed amigal for fabry disease (phase 2), plicera for gaucher disease (phase 2), amicus, shire to develop and commercialize compounds  -  Nov 12, 2007 FDA news (subscription),...which is in phase ii trials for fabry disease, plicera (isofagomine tartrate), which is in phase ii clinical trials for gaucher disease, family’s unused garage converted into cool pad for teen  -  Nov 8, 2007 Knoxville News Sentinel,...who loves music and photography and plays lacrosse, has a rare genetic disorder called fabry's disease. he needs costly enzyme replacement therapy every buyins.net: hte, nal, mpz, nbf, plx, chnr have been removed from ...  -  Nov 6, 2007 Insurance News Net (press release),...is also developing prx-102, a proprietary alpha galactosidase enzyme for the treatment of fabry disease, a genetic lysosomal storage disorder in humans, shire human genetic therapies appoints dr. whaijen soo to manage ...  -  Nov 21, 2007 Oxfordshire Bioscience Network (press release),...usa and canada), replagalâ„¢ for the treatment of fabry disease (approved and marketed in europe) and dynepoâ„¢ for the treatment of anemia in patients with amicus therapeutics announces third quarter 2007 financial results  -  Oct 31, 2007 Trading Markets (press release),...amigal(tm) for fabry disease and plicera(tm) for gaucher disease by yearend," stated john f. crowley, ceo of amicus therapeutics. on a reported basis, shire goes from strength to strength with its adhd drugs  -  Nov 2, 2007 Pharma Times (subscription),...benefiting from new launches in europe. replagal (agalsidasealfa), for the treatment of fabry disease, contributed $40.7 million tothe coffers, up 26%, shire goes from strength to strength with its adhd drugs  -  Nov 2, 2007 Pharma Times (subscription),...benefiting from new launches in europe. replagal (agalsidase alfa), for the treatment of fabry disease, contributed $40.7 million to the coffers, further upgrade to 2007 financial guidance based on strong revenue ...  -  Nov 1, 2007 PR Newswire (press release),...with exchange rate movements against the us dollar accounting for the remaining 9% increase. human genetic therapies replagal - fabry disease sales for Quick takes on health  -  Oct 17, 2007 Rochester Democrat and Chronicle,The session will also include a review of psychosocial services available locally to teens and children with Fabry disease and information on Fabrazyme Daddy's Little Girl (The Update)  -  Oct 15, 2007 ProgressiveU.org,I have grown to understand the innocence in my text when exclaiming that my father, who was 47 at the time and living with Fabry's Disease, was such a Daddy's Little Girl  -  Oct 10, 2007 ProgressiveU.org,There are a lot of symptoms of Fabry disease such as: damaging of the nerves in the body, severe depression, and/or short term memory loss, but he tries his Diseases without clout  -  Oct 9, 2007 Checkbiotech.org (press release),Last year, the FDA approved one of Genzyme's orphan drugs: Fabrazyme, which can reverse kidney disease caused by Fabry disease, a metabolic genetic disorder Genzyme Receives Approval to Market Elaprase(R) in Japan  -  Oct 4, 2007 CNNMoney.comThe company also markets Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; My water torture hell  -  Sep 25, 2007 The Sun,But thanks to new treatment for Anderson Fabry disease – developed through trials in which George participated – he’s alive and well taking each day at a Amicus Therapeutics announces plans to present phase 1 data for ...  -  Sep 20, 2007 Checkbiotech.org (press release),Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher Genzyme expands flagship facility  -  Sep 19, 2007 In-PharmaTechnologist.com,Since then a further four products have been introduced to the facility including Fabrazyme (agalsidase beta) for Fabry disease, and Myozyme (alglucosidase Genzyme Begins $150 Million Expansion of Boston Manufacturing Facility  -  Sep 19, 2007 Boston/SF,Three are manufactured there: Cerezyme; Fabrazyme(R) (agalsidase beta) for Fabry disease; and Myozyme(R) (alglucosidase alfa) for Pompe disease. Shire Appoints Sylvie Gregoire President of Human Genetic ...  -  Sep 24, 2007 CNNMoney.comIn addition, REPLAGAL(TM), for the treatment of Fabry disease, which is available in Europe and other regions outside of the US, continues to perform well. Shire deal might create 650 jobs  -  Sep 20, 2007 Boston Globe,Another of the company's drugs, Replagal, is not yet approved for use by the federal Food and Drug Administration for Fabry disease, a rare genetic disorder Former teacher to stand trial on sex, drug charges  -  Sep 7, 2007 ChronicleHerald.ca,The Canadian Fabry Disease Initiative will evaluate the effectiveness of two forms of the only known therapy produced by different drug companies. Policy needed  -  Sep 5, 2007 Mississauga News,Genzyme Canada makes fabrazyme for Fabry disease. I have Fabry disease, a rare genetic disorder as well as my daughter, grandson, and granddaughter. Help for Fabry patients  -  Aug 23, 2007 SpiritIndia,...at Birmingham (UAB) have discovered the first successful treatment to stop progressive kidney function loss in patients suffering from Fabry disease. Prescription drug cards offered  -  Sep 6, 2007 Brainerd Daily Dispatch,...immunologic disorders, Crohn's disease, Gaucher disease, pulmonary hypertension, Fabry disease, MPS 1, blood dyscrascia, growth hormone deficiency, Combination Therapy Benefits Fabry Disease Patients  -  Aug 6, 2007 Renal and Urology News,..."This work shows for the first time that it is possible to stop progressive decline of kidney function in patients who have Fabry disease with advanced Combination Therapy Stops Loss Of Kidney Function In Rare Genetic ...  -  Jul 27, 2007 Science Daily (press release)..."While Fabry disease is very rare, our study shows that controlling urine protein excretion will slow progression of kidney disease, even though the Breakthrough seen for Fabry disease  -  Jul 26, 2007 United Press InternationalResearchers at the University of Alabama saw improved kidney function in 11 patients with Fabry disease, a rare genetic problem, after they were given an Amicus Therapeutics Announces Second Quarter 2007 Financial Results  -  Aug 7, 2007 CNNMoney.com..."We expect to deliver on three significant clinical milestones by the end of 2007: Phase II data for Amigal(TM) for Fabry disease; preliminary Phase II data Combination Therapy Halts Kidney Function Loss in Genetic Disease  -  Jul 26, 2007 MedPage Today,The treatment for Fabry's disease, an X-linked disorder caused by lysosomal-galactosidase A deficiency, carried an average yearly cost per patient of about 2006 Sales of Antibodies & Proteins  -  Aug 6, 2007 PipelineReview.com (press release),2006 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented Analysis: Street betting on Amicus' drugs  -  Jul 11, 2007 United Press InternationalHowever, the company's most advanced compound -- Amigal for Fabry disease -- is in phase 2 with data expected later this year, so it's difficult to predict Genzyme Boosts Second-Quarter Profit, Raises Forecast (Update2)  -  Jul 25, 2007 BloombergSales of Fabrazyme, which treats Fabry disease, rose 17 percent to $104.3 million. Medicines for rare ailments account for almost half of the Genzyme's Paladin Expands Distribution Agreement with Shire HGT to Include ...  -  Aug 8, 2007 Earthtimes.orgPaladin will be distributing ELAPRASE(TM) (idursulfase) for Hunter syndrome in addition to REPLAGAL® (agalsidase alfa) for Fabry disease. UPDATE 2-Genzyme 2nd-qtr profit rises; raises 2007 outlook  -  Jul 25, 2007 Reuters...while sales of Fabrazyme, a treatment for Fabry disease, which causes certain fats to build up in blood vessels, rose 17 percent to $104.3 million. Highest US Honor for Technological Innovation Awarded to Genzyme  -  Jul 26, 2007 CNW Telbec (Communiqués de presse),Fabrazyme for Fabry disease; Aldurazyme (developed with partner BioMarin Pharmaceutical) for MPS I disease; and Myozyme for Pompe disease. Compnay receives White House honours  -  Jul 26, 2007 Mississauga News,...for Gaucher disease, fabrazyme for Fabry disease, aldurazyme (developed with BioMarin Pharmaceutical) for MPS I disease and myozyme for Pompe disease. Genzyme Q2 Profit Rises On Strong Revenues; EPS Beats View; Lifts ...  -  Jul 25, 2007 Trading Markets,Myozyme sales, for the rare muscle disorder Pompe disease, surged to $46.7 million from $6.5 million, while Fabry disease treatment Fabrazyme sold 17% more Zacks Broker Upgrades: Marvell, Genzyme, Praxair, Starwood Hotels  -  Jul 27, 2007 Business Wire (press release),Genzyme continues to grow its presence in the LSD franchise, based on its flagship Coenzyme product line, along with Fabrazyme (Fabry disease) and Shire Slips To Q2 Loss On Write-off Of Assets; Non-GAAP Net Income ...  -  Jul 26, 2007 RTT News,Replagal, a long-term enzyme replacement therapy for patients with Fabry Disease, anticonvulsant drug Carbatrol and Xagrid, a treatment for a chronic Shire plc: 2007 Guidance Upgraded as Revenue Growth Accelerates  -  Jul 26, 2007 PR Newswire (press release),REPLAGAL - Fabry disease Sales for the three months to June 30, 2007 were US$31.9 million (2006: US$28.3 million). This increase of 13% is primarily due to Search the web for more resources on   Web health.mongabay.com Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com Disclaimer: Contact a physician with regard to health concerns. Email requests for further health information will be discarded. The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site. Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links. COPYRIGHT 2006 MONGABAY.COM